5 completed, 1 active not recruiting, 1 unknown. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Urinary Bladder Cancer: new trials by email Literature Review of Urinary Bladder Cancer trials Research Report on Urinary Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
| A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study nivolumab 480mg, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg - Urinary Bladder Cancer, Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-01-07 | 2022-08-12 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation - Urinary Bladder Cancer, Melanoma | Phase 1 | Active not recruiting | USWM CT, LLC | 71 | 2017-05-15 | 2026-06-04 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
| Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 23 | 2016-05-31 | 2023-09-18 |
| Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 12 | 2016-01-01 | 2020-03-10 |
| Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans - Breast Cancer, Prostate Cancer | Phase 1 | Completed | Copenhagen University Hospital, Rigshospitalet | 10 | 2015-05-01 | 2015-08-24 |
Urinary Bladder Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Liposarcoma, Myxoid (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1)
Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Urinary Bladder Diseases (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Urogenital Neoplasms (6) · Urologic Neoplasms (6) · Neoplasms by Histologic Type (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Bronchial Neoplasms (2) · Carcinoma (2)
Nivolumab (2) · Adjuvants, Pharmaceutic (1) · Administration, Intravesical (1) · Capecitabine (1) · Docetaxel (1) · Ipilimumab (1) · Mitomycin (1) · Neoadjuvant Therapy (1) · Positron-Emission Tomography (1) · Radiation (1) · poly ICLC (1)
Taris Biomedical LLC (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · BioNTech US Inc. (1) · Copenhagen University Hospital, Rigshospitalet (1) · NanOlogy, LLC (1) · USWM CT, LLC (1)
United States (4) · Netherlands (3) · Canada (1) · Denmark (1)
Adriaan D. Bins, MD PhD (1) · David Hong, MD (1) · Donald Lamm, MD, FACS (1) · Dorthe Skovgaard, MD, PhD (1) · Johannes Witjes, MD (1) · Mark DeMario, MD (1) · Siamak Daneshmand, MD (1)
PMID 22213823, PMID 32002290, PMID 33064988, PMID 33294862, PMID 35431132, PMID 36624315
2014 (1), 2016 (1)